Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience

Dabrafenib is a potent BRAF-kinase inhibitor. Its activity was evaluated on 40 consecutive metastatic melanoma patients (pts) harboring the V600BRAF mutations. Dabrafenib was administered orally at the dosage of 150 mg b.i.d. daily. ORR was 82%, with 7% CR, 62% PR, 13% SD and 18% PD. The median PFS...

Descripción completa

Detalles Bibliográficos
Autores principales: Cocorocchio, E, Gandini, S, Alfieri, S, Battaglia, A, Pennacchioli, E, Tosti, G, Spadola, G, Barberis, M, Leo, M Di, Riviello, C, Pala, L, Intelisano, A, Martinoli, C, Ferrucci, PF
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4778691/
https://www.ncbi.nlm.nih.gov/pubmed/26981153
http://dx.doi.org/10.3332/ecancer.2016.624
_version_ 1782419513148440576
author Cocorocchio, E
Gandini, S
Alfieri, S
Battaglia, A
Pennacchioli, E
Tosti, G
Spadola, G
Barberis, M
Leo, M Di
Riviello, C
Pala, L
Intelisano, A
Martinoli, C
Ferrucci, PF
author_facet Cocorocchio, E
Gandini, S
Alfieri, S
Battaglia, A
Pennacchioli, E
Tosti, G
Spadola, G
Barberis, M
Leo, M Di
Riviello, C
Pala, L
Intelisano, A
Martinoli, C
Ferrucci, PF
author_sort Cocorocchio, E
collection PubMed
description Dabrafenib is a potent BRAF-kinase inhibitor. Its activity was evaluated on 40 consecutive metastatic melanoma patients (pts) harboring the V600BRAF mutations. Dabrafenib was administered orally at the dosage of 150 mg b.i.d. daily. ORR was 82%, with 7% CR, 62% PR, 13% SD and 18% PD. The median PFS and OS were seven and 17 months, respectively (median follow-up: 8.5 months). Increased risk of progression was found in pts with elevated LDH, ECOG PS >1 and more than two metastatic sites. Grade 3–4 adverse events were recorded in 4 pts. In this retrospective analysis, Dabrafenib confirmed its role as the standard clinical option in metastatic melanoma pts.
format Online
Article
Text
id pubmed-4778691
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-47786912016-03-15 Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience Cocorocchio, E Gandini, S Alfieri, S Battaglia, A Pennacchioli, E Tosti, G Spadola, G Barberis, M Leo, M Di Riviello, C Pala, L Intelisano, A Martinoli, C Ferrucci, PF Ecancermedicalscience Clinical Study Dabrafenib is a potent BRAF-kinase inhibitor. Its activity was evaluated on 40 consecutive metastatic melanoma patients (pts) harboring the V600BRAF mutations. Dabrafenib was administered orally at the dosage of 150 mg b.i.d. daily. ORR was 82%, with 7% CR, 62% PR, 13% SD and 18% PD. The median PFS and OS were seven and 17 months, respectively (median follow-up: 8.5 months). Increased risk of progression was found in pts with elevated LDH, ECOG PS >1 and more than two metastatic sites. Grade 3–4 adverse events were recorded in 4 pts. In this retrospective analysis, Dabrafenib confirmed its role as the standard clinical option in metastatic melanoma pts. Cancer Intelligence 2016-03-03 /pmc/articles/PMC4778691/ /pubmed/26981153 http://dx.doi.org/10.3332/ecancer.2016.624 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Cocorocchio, E
Gandini, S
Alfieri, S
Battaglia, A
Pennacchioli, E
Tosti, G
Spadola, G
Barberis, M
Leo, M Di
Riviello, C
Pala, L
Intelisano, A
Martinoli, C
Ferrucci, PF
Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience
title Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience
title_full Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience
title_fullStr Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience
title_full_unstemmed Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience
title_short Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience
title_sort dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4778691/
https://www.ncbi.nlm.nih.gov/pubmed/26981153
http://dx.doi.org/10.3332/ecancer.2016.624
work_keys_str_mv AT cocorocchioe dabrafenibinmetastaticmelanomaamonocentricreallifeexperience
AT gandinis dabrafenibinmetastaticmelanomaamonocentricreallifeexperience
AT alfieris dabrafenibinmetastaticmelanomaamonocentricreallifeexperience
AT battagliaa dabrafenibinmetastaticmelanomaamonocentricreallifeexperience
AT pennacchiolie dabrafenibinmetastaticmelanomaamonocentricreallifeexperience
AT tostig dabrafenibinmetastaticmelanomaamonocentricreallifeexperience
AT spadolag dabrafenibinmetastaticmelanomaamonocentricreallifeexperience
AT barberism dabrafenibinmetastaticmelanomaamonocentricreallifeexperience
AT leomdi dabrafenibinmetastaticmelanomaamonocentricreallifeexperience
AT rivielloc dabrafenibinmetastaticmelanomaamonocentricreallifeexperience
AT palal dabrafenibinmetastaticmelanomaamonocentricreallifeexperience
AT intelisanoa dabrafenibinmetastaticmelanomaamonocentricreallifeexperience
AT martinolic dabrafenibinmetastaticmelanomaamonocentricreallifeexperience
AT ferruccipf dabrafenibinmetastaticmelanomaamonocentricreallifeexperience

Ejemplares similares